Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
Part of paid clinical trials in Clearwater, Florida.
- Sponsor
- Viatris Innovation GmbH
- Study ID
- NCT06475742
- Phase
- PHASE3
- Status
- Enrolling By Invitation
Conditions
- Lupus Erythematosus, Systemic
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Cenerimod — DRUGFilm-coated tablets at a dose of 4 mg.
Study Details
The goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients with moderate to severe symptoms of systemic lupus erythematosus. The main questions it aims to answer are: * Whether cenerimod causes any adverse effects ('side effects') when given on top of drugs already being given for systemic lupus erythematosus. * How well cenerimod works to reduce symptoms of systemic lupus erythematosus when taken for at least 1 year and up to 3 years. Participants taking part in this study will have already taken part in another study, where they received either cenerimod or placebo (look-alike substance containing no active drug) for 1 year. In this clinical study approximately 680 participants will receive cenerimod (on top of drugs already being given for systemic lupus erythematosus) for at least 1 year and up to 3 years.
Key Dates
- Start date
- Jul 30, 2024
- Status verified
- Aug 2025
- Primary completion
- May 31, 2028
- Completion
- May 31, 2028
Study Design
- Enrollment
- 680 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Cenerimod 4 mgParticipants will receive oral cenerimod once daily in addition to background systemic lupus erythematosus therapy, for at least 1 year and up to a maximum of 3 years.
Primary Outcome Measure
Treatment-emergent adverse events [ Time Frame: Day 1 (post dose) to a maximum of 3.5 years ]
Locations (13)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Clinical Research of West Florida, Inc. | Clearwater | Florida | 33765 | - |
| Omega Research MetroWest, LLC | DeBary | Florida | 32713 | - |
| Allied Biomedical Research Institute | Miami | Florida | 33155 | - |
| D&H National Research Centers INC | Miami | Florida | 33155 | - |
| Professional research Center INC | Miami | Florida | 33172 | - |
| SouthCoast Research Center, Inc. | Miami | Florida | 33136 | - |
| San Marcus Res Clin Inc. | Miami Lakes | Florida | 33014 | - |
| Accurate Clinical Research Inc. - Lake Charles | Lake Charles | Louisiana | 70605 | - |
| RB Wellness Clinic | Las Vegas | Nevada | 89102 | - |
| Accurate Clinical Research Inc - (Najam) | Baytown | Texas | 77521 | - |
| Novel Research LLC | Bellaire | Texas | 77401 | - |
| Accurate Clinical Research Inc. | Houston | Texas | 77089 | - |
| Sun Research | San Antonio | Texas | 78215 | - |
Find similar trials in Clearwater, FL
Related Studies
- A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)PHASE2 · Recruiting · Novartis Pharmaceuticals · Birmingham, Alabama
- A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLEPHASE1/PHASE2 · Recruiting · AstraZeneca · San Francisco, California
- A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)PHASE2 · Recruiting · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Scottsdale, Arizona
- A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular TreatmentPHASE3 · Recruiting · Viatris Innovation GmbH · Kissimmee, Florida